Ipsen Presents Positive Results For Phase I, Phase IIa BIM23A760 Studies
Ipsen has announced the results of phase I and phase IIa clinical studies for BIM23A760, designed and developed by its peptide engineering platform. This molecule targets two patho-physiological
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.